Lifevantage Corporation announced release of a new formulation of Protandim in Japan with potent Nrf2 activation as well as the implementation of necessary warehousing and product fulfillment resources to be fully operational on the ground in Japan. The formulation being distributed in Japan is the subject of a placebo controlled, double blind clinical study being conducted at Colorado State University. Preliminary data from that study show the product to be a potent oxidative stress reducer.